Skip to main content

Vaxcyte, Inc.

corporate_fare Company Profile

Vaxcyte, Inc.

PCVX·NASDAQ·Life Sciences·CIK 0001649094

We are a clinical-stage vaccine innovation company focused on developing vaccines to protect against bacterial diseases. We use our XpressCF™ cell-free protein synthesis platform to produce complex vaccines. This system aims to create high-fidelity vaccines with enhanced immunological benefits, which differs from conventional cell-based methods. The global vaccine market is large, durable, and growing, driven by routine pediatric vaccinations and increased adult vaccination due to new vaccines, expanded age recommendations, and international adoption. We target areas with significant unmet medical needs, including vaccines that offer broader protection against current and historical strains, and novel vaccines for pathogens without approved treatments. Our selection criteria for target disease areas and vaccine candidates include significant unmet medical need, clear commercial opportunity, efficient market adoption, acceptable biological risk, and established or acceptable clinical pathways. We are using our scalable cell-free protein synthesis platform to develop conjugate and protein vaccine candidates for adult and pediatric indications. Our pipeline includes PCV (Pneumococcal Conjugate Vaccine) candidates, which we believe are among the broadest-spectrum PCV candidates in development, targeting the approximately $8 billion global pneumococcal vaccine market. Pneumococcal disease (PD) is an infection caused by *Streptococcus pneumoniae* bacteria.

Vaxcyte, Inc. (NASDAQ:PCVX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for PCVX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Vaxcyte Establishes New $500M At-The-Market Offering Program, Replacing Prior Agreement
  • Vaxcyte Files Prospectus for New $500M At-The-Market Offering Program
  • Vaxcyte Accelerates VAX-31 into Multiple Phase 3 Trials, Secures Long-Term Manufacturing, and Finalizes $600M Offering
  • Vaxcyte Reports Strong Cash Position and Significant Clinical Progress for VAX-31 Programs
  • Vaxcyte Finalizes $600.2M Public Offering with Full Over-Allotment Exercise

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$766.63M
Diluted EPS
-$5.63
Op. Cash Flow
-$655.58M
Free Cash Flow
-$669.29M
Operating Income
-$923.67M
Cash & Equivalents
$173.96M
Debt / Equity
0.00×
Shares Outstanding
131.06M sh
Source: 10-K · filed 2026-02-24 · accession 0001649094-26-000007
$55.72 +0.60% today
52-week range · as of 2026-11-04 $39.87 – $90.75
Market cap
$8.77B
Volume
1.9M (1.0× avg)
3-mo avg 1.9M
Live data · 2026-11-21 14:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PCVX - Filings & News (Page 2)

PCVX
Feb 24, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $59.16
Real-time Price: $55.72 info
Change: -$3.44 (-6%) info
Market Cap: $8.768B info
PCVX
Feb 24, 2026, 5:19 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $59.16
Real-time Price: $55.72 info
Change: -$3.44 (-6%) info
Market Cap: $8.768B info
PCVX
Feb 24, 2026, 4:37 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $59.16
Real-time Price: $55.72 info
Change: -$3.44 (-6%) info
Market Cap: $8.768B info
PCVX
Feb 24, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $61.35
Real-time Price: $55.72 info
Change: -$5.63 (-9%) info
Market Cap: $8.768B info
PCVX
Feb 02, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $57.40
Real-time Price: $55.72 info
Change: -$1.68 (-3%) info
Market Cap: $8.768B info
PCVX
Jan 30, 2026, 5:12 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $53.57
Real-time Price: $55.72 info
Change: +$2.15 (+4%) info
Market Cap: $8.768B info
PCVX
Jan 29, 2026, 4:01 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $52.82
Real-time Price: $55.72 info
Change: +$2.90 (+5%) info
Market Cap: $8.768B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets